亞太液態切片市場：按最終用戶和國家/地區進行的分析和預測（2024-2033 年）

亞太地區液態切片市場規模預計將從 2024 年的 7.081 億美元增至 2033 年的 29.273 億美元，預測期內複合年成長率高達 17.08%。

液態切片正在成為亞太地區癌症檢測和監測的革命性非侵入性診斷工具。這種新方法創傷性極小，可以提供即時監測以評估治療反應，並有可能檢測早期癌症復發。癌症發病率上升、研究出版物增加以及臨床試驗增加推動了市場的不斷擴大，從而推動了對液態切片測試和產品的需求。對微創診斷技術的偏好導致了更具創新性和更有效率的測試的快速發展。

此外，由於政府採取舉措改善癌症檢測和治療管理，市場正在以更快的速度成長。許多分銷管道，包括線上平台和零售店，都生產液態切片產品，確保了整個全部區域的供應和廣泛的消費者覆蓋範圍。這些因素，加上患者對非侵入性癌症篩檢日益成長的需求，正在推動亞太液態切片市場的巨大發展勢頭，全部區域更有效率、更容易獲得的癌症檢測解決方案鋪平道路。

亞太地區液態切片市場作為癌症監測和檢測的非侵入性替代方法正在迅速擴張，與傳統切片檢查技術相比具有許多優勢。液態切片檢查血液樣本中的循環腫瘤DNA（ctDNA）、RNA和外泌體，從而能夠早期檢測癌症、即時監測和評估治療效果，同時最大程度地減少患者的不適。由於該地區癌症發生率不斷上升，以及對個人化醫療和微創診斷解決方案的需求，這項技術變得越來越受歡迎。

癌症發生率的上升、生物標記檢測技術的發展、以及心臟病學和感染疾病等腫瘤學以外的應用的不斷擴大是推動市場發展的主要因素。政府措施、研究資金的增加以及優先事項的變化正在促進液態切片在精準醫療中的應用不斷擴大。這種日益廣泛的應用得益於政府措施、研究經費的增加以及向精準醫療的轉變。此外，透過線上平台和醫療保健提供者提供的液態切片測試的日益普及，提高了整個亞太地區的可及性並促進了市場採用，並透過早期診斷和更好的治療監測改善了患者的治療效果。

本報告調查了亞太液態切片市場，並總結了主要趨勢、影響市場的因素分析、法律制度、技術發展和專利趨勢、市場規模和預測的變化、各個細分市場和主要國家的詳細分析、競爭格局以及主要企業的概況。

市場區隔:

細分 1：按最終用戶

• 學術和研究機構
• 臨床實驗室
• 製藥和生物技術公司
• 企業
• 其他

細分2：按地區

• 亞太地區
  • 日本
  • 印度
  • 中國
  • 韓國
  • 澳洲
  • 新加坡
  • 其他

目錄

執行摘要

範圍和定義

第1章 市場

• 市場趨勢
• 供應鏈分析：亞太液態切片市場
• 法律規範
• COVID-19 對亞太液態切片市場的影響
• 最近推出的產品/服務
• 贖回情況
• 資金籌措方案
• 產品映射分析
• 市場總規模及滲透率
• 液態切片市場：相關利益者分析
• 政府關於液態切片的舉措
• 市場動態概覽
  • 市場促進因素
  • 市場限制
  • 市場機會

第2章 區域

• 亞太地區
  • 區域概況
  • 市場成長推進因素
  • 市場問題
  • 測試次數
  • 市場規模及預測
  • 中國
  • 日本
  • 印度
  • 澳洲
  • 韓國
  • 新加坡
  • 其他

第 3 章市場：競爭基準化分析與公司簡介

• 公司簡介
  • Sysmex Corporation

第4章調查方法

Introduction to Asia-Pacific Liquid Biopsy Market

The Asia-Pacific liquid biopsy market was valued at $708.1 million in 2024 and is expected to reach $2,927.3 million by 2033, growing at a CAGR of 17.08% during the forecast period 2024-2033. Liquid biopsies are becoming a revolutionary non-invasive diagnostic tool for cancer detection and monitoring in APAC. This novel approach provides real-time monitoring with minimal invasiveness, assesses treatment responses, and has the potential to detect early cancer recurrence detection. There is a greater need for liquid biopsy tests and products as a result of the market's expansion due to the rising prevalence of cancer, rising research publications, and growing clinical trials. More innovative and efficient tests have been developed quickly as a result of the growing preference for minimally invasive diagnostic techniques.

Additionally, the market has grown more quickly as a result of government initiatives that have been implemented to improve cancer detection and treatment management. Many distribution channels, including online platforms and retail outlets, have made liquid biopsy products enhancing accessibility and ensuring broader consumer reach across the region. These factors, along with increasing patient demand for non-invasive cancer screening, are helping the APAC liquid biopsy market gain significant momentum, paving the way for more efficient and accessible cancer detection solutions across the region.

Market Introduction

The APAC Liquid Biopsy Market is expanding quickly as a non-invasive alternative for cancer monitoring and detection, providing a number of benefits over conventional biopsy techniques. With the least amount of discomfort to the patient, liquid biopsy enables early cancer detection, real-time monitoring, and evaluation of treatment responses by examining circulating tumor DNA (ctDNA), RNA, and exosomes from blood samples. Because of the rising incidence of cancer in the area and the need for personalized medicine and minimally invasive diagnostic solutions, this technology is becoming more and more popular.

Rising cancer rates, technological developments in biomarker detection, and the expansion of applications beyond oncology, such as in cardiology and infectious diseases, are the main factors propelling the market's growth. Government initiatives, rising research funding, and a change in priorities are all contributing to the increasing use of liquid biopsy toward precision medicine. The growing adoption of liquid biopsy is supported by government initiatives, increasing research funding, and a shift toward precision medicine. Moreover, the increasing availability of liquid biopsy tests through online platforms and healthcare providers is enhancing accessibility, driving market adoption across APAC, and improving patient outcomes through earlier diagnosis and better treatment monitoring.

Market Segmentation:

Segmentation 1: by End User

• Academic and Research Institutions
• Clinical Laboratories
• Pharmaceutical and Biotechnology
• Companies
• Other End Users

Segmentation 2: by Region

• Asia-Pacific
  • Japan
  • India
  • China
  • South Korea
  • Australia
  • Singapore
  • Rest-of-Asia-Pacific

How can this report add value to an organization?

Product/Innovation Strategy: The Asia-Pacific liquid biopsy market has been segmented based on various categories, such as end user and country.

Competitive Strategy: The Asia-Pacific liquid biopsy market is highly fragmented, with many smaller and private companies constantly entering the market. Key players in the liquid biopsy market analyzed and profiled in the study involve established players that offer various kinds of products and services.

Table of Contents

Executive Summary

Scope and Definition

1 Market

• 1.1 Market Trends
  • 1.1.1 Increasing Product Launches in the Market
  • 1.1.2 Growing Funding by the Key Players in the Market
• 1.2 Supply Chain Analysis: Asia-Pacific Liquid Biopsy Market
• 1.3 Regulatory Framework
  • 1.3.1 Regulation in Other Countries
• 1.4 COVID-19 Impact on Asia-Pacific Liquid Biopsy Market
• 1.5 Recently Launched Product/Services
• 1.6 Reimbursement Scenario
• 1.7 Financing Scenario
  • 1.7.1 Key Players Patent Portfolio
  • 1.7.2 Key Players Stratification as per Raised Financing Value
  • 1.7.3 Key Players Financing Analysis (by Company)
• 1.8 Product Mapping Analysis
  • 1.8.1 By Technology
  • 1.8.2 By Sample
  • 1.8.3 By Circulating Biomarker
  • 1.8.4 By Clinical Application
• 1.9 Total Addressable Market and Penetration
• 1.1 Liquid Biopsy Market: Stakeholder Analysis (N=30)
  • 1.10.1 Physicians' Perception
  • 1.10.2 Payer's Perception
  • 1.10.3 Investors' Perception
• 1.11 Liquid Biopsy Government Initiatives
• 1.12 Market Dynamics Overview
  • 1.12.1 Market Drivers
    • 1.12.1.1 Rising Burden of Cancer
    • 1.12.1.2 Growing Research Publications and Clinical Trials in Liquid Biopsy
    • 1.12.1.3 Growing Adoption and Demand of Minimally Invasive Cancer Detection Methods
  • 1.12.2 Market Restraints
    • 1.12.2.1 Technical Limitations in Liquid Biopsy
    • 1.12.2.2 Uncertain Reimbursement and Recommendations for Liquid Biopsy Tests
  • 1.12.3 Market Opportunities
    • 1.12.3.1 Integration of AI in Liquid Biopsy
    • 1.12.3.2 Use of Liquid Biopsy for Precision Medicine in Oncology

2 Regions

• 2.1 Asia-Pacific
  • 2.1.1 Regional Overview
  • 2.1.2 Driving Factors for Market Growth
  • 2.1.3 Factors Challenging the Market
  • 2.1.4 Test Volume
  • 2.1.5 Market Size and Forecast
    • 2.1.5.1 By End User
  • 2.1.6 China
    • 2.1.6.1 Test Volume
    • 2.1.6.2 Market Size and Forecast
      • 2.1.6.2.1 By End User
  • 2.1.7 Japan
    • 2.1.7.1 Test Volume
    • 2.1.7.2 Market Size and Forecast
      • 2.1.7.2.1 By End User
  • 2.1.8 India
    • 2.1.8.1 Test Volume
    • 2.1.8.2 Market Size and Forecast
      • 2.1.8.2.1 By End User
  • 2.1.9 Australia
    • 2.1.9.1 Test Volume
    • 2.1.9.2 Market Size and Forecast
      • 2.1.9.2.1 By End User
  • 2.1.10 South Korea
    • 2.1.10.1 Test Volume
    • 2.1.10.2 Market Size and Forecast
      • 2.1.10.2.1 By End User
  • 2.1.11 Singapore
    • 2.1.11.1 Test Volume
    • 2.1.11.2 Market Size and Forecast
      • 2.1.11.2.1 By End User
  • 2.1.12 Rest-of-Asia-Pacific
    • 2.1.12.1 Test Volume
    • 2.1.12.2 Market Size and Forecast
      • 2.1.12.2.1 By End User

3 Markets - Competitive Benchmarking & Company Profiles

• 3.1 Company Profiles
  • 3.1.1 Sysmex Corporation
    • 3.1.1.1 Overview
    • 3.1.1.2 Top Products
    • 3.1.1.3 Top Competitors
    • 3.1.1.4 Key Personnel
    • 3.1.1.5 Analyst View

4 Research Methodology

• 4.1 Data Sources
  • 4.1.1 Primary Data Sources
  • 4.1.2 Secondary Data Sources
  • 4.1.3 Data Triangulation
• 4.2 Market Estimation and Forecast

List of Figures

• Figure 1: Asia-Pacific Liquid Biopsy Market, $Million, 2024, 2028, and 2033
• Figure 2: Key Events to Keep Track of in the Liquid Biopsy Market
• Figure 3: Impact of COVID-19 on Liquid Biopsy Market
• Figure 4: Patent Published (by Country), January 2021-May 2024
• Figure 5: Number of Liquid Biopsy Patents (by Year), January 2021-May 2024
• Figure 6: Financing Analysis (by Latest Deal Amount), $Million, FY2023-2024
• Figure 7: Asia-Pacific Liquid Biopsy Market Scenario, 2023
• Figure 8: Frequently Used Technology in Liquid Biopsy
• Figure 9: Most Important Factors for Adoption of NGS-Based Liquid Biopsy
• Figure 10: Treatment Guidelines for Treatment of Cancer Patients
• Figure 11: Major Challenges Faced While Performing Liquid Biopsy
• Figure 12: Average Cost of Technologies for the Liquid Biopsy Market (N=30 )
• Figure 13: Cost Difference Across Different End Users for the Liquid Biopsy Market
• Figure 14: Key Factors for Determining Reimbursement Possibility for the Liquid Biopsy Market
• Figure 15: Estimated Cancer Incidence in 2020 and 2040
• Figure 16: Estimated New Cancer Cases (2022-2045): Both Sexes, Ages 0-85
• Figure 17: Upsurge in Research Publications in Liquid Biopsy, 2015-2023
• Figure 18: Comparison of Liquid Biopsy vs. Tissue Biopsy
• Figure 19: Asia-Pacific Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 20: Asia-Pacific Liquid Biopsy Market, $Million, 2023-2033
• Figure 21: China Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 22: China Liquid Biopsy Market, $Million, 2023-2033
• Figure 23: Japan Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 24: Japan Liquid Biopsy Market, $Million, 2023-2033
• Figure 25: India Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 26: India Liquid Biopsy Market, $Million, 2023-2033
• Figure 27: Australia Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 28: Australia Liquid Biopsy Market, $Million, 2023-2033
• Figure 29: South Korea Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 30: South Korea Liquid Biopsy Market, $Million, 2023-2033
• Figure 31: Singapore Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 32: Singapore Liquid Biopsy Market, $Million, 2023-2033
• Figure 33: Rest-of-Asia-Pacific Liquid Biopsy Market, Test Volume, Thousand, 2023-2033
• Figure 34: Rest-of-Asia-Pacific Liquid Biopsy Market, $Million, 2023-2033
• Figure 35: Data Triangulation
• Figure 36: Top-Down and Bottom-Up Approach
• Figure 37: Assumptions and Limitations

List of Tables

• Table 1: Market Snapshot
• Table 2: Asia-Pacific Liquid Biopsy Market, Market Opportunities
• Table 3: Product Launches, January 2021-April 2024
• Table 4: Some of the Strategic Funding, January 2022-April 2024
• Table 5: Launched Liquid Biopsy Tests from Players in the Liquid Biopsy Market
• Table 6: Reimbursement Scenario for Key Players' Offerings in the Liquid Biopsy Market
• Table 7: Liquid Biopsy Market: Key Players Patent Portfolio
• Table 8: Liquid Biopsy Product Mapping Analysis (by Technology)
• Table 9: Liquid Biopsy Product Mapping Analysis (by Sample)
• Table 10: Liquid Biopsy Product Mapping Analysis (by Circulating Biomarker)
• Table 11: Liquid Biopsy Product Mapping Analysis (by Clinical Application)
• Table 12: Government Initiatives for Liquid Biopsies
• Table 13: Impact Analysis of Market Navigating Factors, 2023-2033
• Table 14: Liquid Biopsy Market (by Region), $Million, 2023-2033
• Table 15: Asia-Pacific Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 16: China Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 17: Japan Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 18: India Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 19: Australia Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 20: South Korea Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 21: Singapore Liquid Biopsy Market (by End User), $Million, 2023-2033
• Table 22: Rest-of-Asia-Pacific Liquid Biopsy Market (by End User), $Million, 2023-2033